TIL
Instil Bio, Inc.
$8.15
+1.62%
$54.4M
No data for this timeframe.
Vol
Market Cap$54.4M
Cap SizeMicro Cap
Inst. Holders4 funds
Inst. Value$3.8M
Inst. Activity1 buys / 1 sells
Reddit Sentiment71° Bullish
SEC Reports4
Press Releases1
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. NY·CIK 0001789769·Prev Close $8.02
Recent Activity
May 15, 2026
SEC
Instil Bio reported Q1 2026 GAAP EPS of -$0.62, a slight miss vs consensus -$0.59, but as a pre-revenue biotech the abso
8-K — Impact 4/10
May 15, 2026
SEC
Instil Bio reported Q1 2026 GAAP EPS of -$0.62, beating the -$0.59 consensus by 5.1% (a beat), with no revenue. The comp
PRESS-RELEASE — Impact 4/10
Apr 24, 2026
SEC
Instil Bio, Inc. filed a definitive additional proxy materials statement (DEFA14A) related to a shareholder vote. The fi
DEFA14A — Impact 2/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — NEW
67,800 shares ($745.8K)
Inst.
BANK OF AMERICA CORP — NEAR_EXIT
4 shares ($44.00)
May 15, 2026
earnings
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Mar 27, 2026
Press
Instil Bio reported its Q4 and full-year 2025 financial results, showing a reduced net loss compared to the prior year d
Impact 5/10
Price Targets
Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$7.00 (Jan 2026)
Current $8.15
Low $7.00
Median $7.00
High $7.00
1 analysts
$7.00
$7.00
Analyst Ratings
2Strong Buy
3Buy
2Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jan 7, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.35 ▲ +16.7% | $-0.35 — $-0.35 | 89% YoY | 1 |
| Next Q | $-0.17 ▲ +48.5% | $-0.17 — $-0.17 | 92% YoY | 1 |
| Current FY | $-1.17 ▲ +27.3% | $-1.17 — $-1.17 | 89% YoY | 1 |
Latest Reports
NEUTRAL
8-K
4/10
Instil Bio reported Q1 2026 GAAP EPS of -$0.62, a slight miss vs consensus -$0.59, but as a pre-revenue biotech the abso
May 15, 2026
NEUTRAL
PRESS-RELEASE
4/10
Instil Bio reported Q1 2026 GAAP EPS of -$0.62, beating the -$0.59 consensus by 5.1% (a beat), with no revenue. The comp
May 15, 2026
MIXED
Press
5/10
Instil Bio reported its Q4 and full-year 2025 financial results, showing a reduced net loss compared to the prior year d
Mar 27, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $2.1M | — |
| MORGAN STANLEY | $978.8K | DOUBLED |
| RENAISSANCE TECHNOLOGIES LLC | $745.8K | NEW |
| BANK OF AMERICA CORP | $44.00 | NEAR_EXIT |
Reddit Sentiment
71°
Bullish
Bearish
Neutral
Bullish
4 institutional holders with $3.8M total value (347,843 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, RENAISSANCE.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 191,060 | $2.1M | 54.9% | — |
| 2 | MORGAN STANLEY | 88,979 | $978.8K | 25.6% | DOUBLED +397.7% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 67,800 | $745.8K | 19.5% | NEW |
| 4 | BANK OF AMERICA CORP /DE/ | 4 | $44.00 | 0.0% | NEAR_EXIT -99.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 67,800 | — | $745.8K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 599 | 4 | -99.3% | $44.00 | 2025-Q4 |
| UBS Group AG | TRIM | 16,219 | 5,621 | -65.3% | $100.4K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 1,040 | 599 | -42.4% | $10.7K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 70,655 | 0 | -100.0% | $0.00 | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 19,351 | 96,308 | +397.7% | $2.0M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 104,943 | 70,655 | -32.7% | $1.5M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 34 | 1,040 | +2958.8% | $21.7K | 2025-Q2 |
| FMR LLC | NEAR_EXIT | 79 | 5 | -93.7% | $110.00 | 2025-Q2 |
| MORGAN STANLEY | TRIM | 36,041 | 19,351 | -46.3% | $335.9K | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 91,086 | 17,280 | -81.0% | $300.0K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 96,855 | 133,755 | +38.1% | $2.6M | 2024-Q4 |
| UBS Group AG | DOUBLED | 131 | 91,086 | +69431.3% | $1.7M | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 4,872 | 36,041 | +639.8% | $688.0K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | 2,981 | 0 | -100.0% | $0.00 | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 2,981 | — | $200.7K | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
4 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 3.5/10.
NEUTRAL
8-K
4/10
Instil Bio reported Q1 2026 GAAP EPS of -$0.62, a slight miss vs consensus -$0.59, but as a pre-reve
May 15, 2026
NEUTRAL
PRESS-RELEASE
4/10
Instil Bio reported Q1 2026 GAAP EPS of -$0.62, beating the -$0.59 consensus by 5.1% (a beat), with
May 15, 2026
NEUTRAL
DEFA14A
2/10
Instil Bio, Inc. filed a definitive additional proxy materials statement (DEFA14A) related to a shar
Apr 24, 2026
NEUTRAL
8-K
4/10
Instil Bio, Inc. (TIL) dismissed Deloitte & Touche LLP as its independent auditor and appointed RSM
Apr 3, 2026
Historical analyst distribution (last covering-analyst action Jan 2026): 71% buy across 7 analysts — 2 strong buy, 3 buy, 2 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$7.00 mean target (Jan 2026)
$7.00 Low
$7.00 High
| Metric | Value |
|---|---|
| Current Price | $8.15 |
| Target Low | $7.00 |
| Target Mean | $7.00 |
| Target Median | $7.00 |
| Target High | $7.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.35 | $-0.35 | $-0.35 | 89.2% | +16.7% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.17 | $-0.17 | $-0.17 | 91.5% | +48.5% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-1.17 | $-1.17 | $-1.17 | 89.1% | +27.3% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.350 | |
| 7d ago | $-0.420 | +0.070 |
| 30d ago | $-0.420 | +0.070 |
| 60d ago | $-1.217 | +0.867 |
| 90d ago | $-1.217 | +0.867 |
1 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jan 7, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 2 | 3 | 2 | 0 | 0 | 71% | |
| Apr 1, 2026 | 2 | 3 | 2 | 0 | 0 | 71% | |
| Mar 1, 2026 | 2 | 3 | 3 | 0 | 0 | 63% | |
| Feb 1, 2026 | 2 | 3 | 3 | 0 | 0 | 63% | |
| Jan 1, 2026 | 3 | 3 | 2 | 0 | 0 | 75% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
71°
Bullish
Bearish
Neutral
Bullish
3 mentions
3 bullish
0 bearish
3 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 22, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 22, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 27, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
IOVA boom or bust?
▲ 1
💬 0
⚡ 0.5
Biotech companies $IOVA and $NMRA DD
▲ 1
💬 1
⚡ 0.0
May 15, 2026
earnings
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
earnings_calendar
TIL Q1 2026 Earnings Scheduled — 2026-05-13
May 11, 2026
earnings_calendar
TIL Q1 2026 Earnings Scheduled — 2026-05-11
Mar 27, 2026
earnings
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Mar 2, 2026
earnings_calendar
TIL Q4 2025 Earnings After Market Close — 2026-03-02